[vc_row top_margin=”none” el_position=”first”] [vc_column top_margin=”none”] [mc_carousel id=”carousel” carousel_images=”2773,2772,2771,2770″ features_images_loop=”1″ lightbox_icon_color=”blue_light” autoplay=”0″ pause_on_hover=”1″ scroll=”1″ effect=”scroll” easing=”swing” duration=”500″ top_margin=”page_margin_top_section” el_position=”first last”] [/vc_column] [/vc_row] [vc_row top_margin=”none” el_position=”last”] [vc_column top_margin=”none”] [vc_column_text el_position=”first last”]

73% of Kidney Cancer Patients Respond to Inlyta-Keytruda Combo, Trial Shows
February, 2018
https://immuno-oncologynews.com/2018/02/16/inlyta-keytruda-combo-kidney-cancer-phase-1b-trial/

GU Cancer Symposium 2018
Tecentriq-Avastin Combo In Advanced Kidney Cancer
February, 2018
https://immuno-oncologynews.com/2018/02/12/tecentriq-avastin-combination-roche-genetech-reduces-risk-disease-worsening-advanced-kidney-cancer-phase-3-trial/

Sunitinib or Everolimus First-Line for Kidney Cancer
Journal of Clinical Oncology
Medscape
July 24, 2014
http://www.medscape.com/viewarticle/828815

Enzyme may halt tumor growth in kidney cancer
Medical News Today
July 22, 2014
http://www.medicalnewstoday.com/articles/279929.php

Expanding the playing Field: Immune-Based Therapy Shows Potential
NCI Cancer Bulletin
June, 2012
http://www.cancer.gov/clinicaltrials/results/summary/2012/PD-1-immunotherapy0612

[/vc_column_text] [/vc_column] [/vc_row]